938 related articles for article (PubMed ID: 20061178)
1. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
Abdollahi A; Folkman J
Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
[TBL] [Abstract][Full Text] [Related]
2. [Novel angiogenesis inhibitors for molecular target therapy of cancer].
Osada H; Kakeya H
Nihon Rinsho; 2004 Jul; 62(7):1257-63. PubMed ID: 15283141
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic therapies in cancer: achievements and open questions.
Ruegg C; Mutter N
Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
[TBL] [Abstract][Full Text] [Related]
4. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
5. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand".
Rak J; Yu JL
Semin Cancer Biol; 2004 Apr; 14(2):93-104. PubMed ID: 15018893
[TBL] [Abstract][Full Text] [Related]
6. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
7. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
[TBL] [Abstract][Full Text] [Related]
8. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
Qiu H; Wang GM
Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
[TBL] [Abstract][Full Text] [Related]
9. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
11. Target-based therapies in breast cancer: current status and future perspectives.
Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
[TBL] [Abstract][Full Text] [Related]
12. Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.
Ribatti D
Cancer Treat Rev; 2011 Aug; 37(5):344-52. PubMed ID: 21435792
[TBL] [Abstract][Full Text] [Related]
13. The angiogenic process as a therapeutic target in cancer.
Bridges EM; Harris AL
Biochem Pharmacol; 2011 May; 81(10):1183-91. PubMed ID: 21382350
[TBL] [Abstract][Full Text] [Related]
14. TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives.
Stegehuis JH; de Wilt LH; de Vries EG; Groen HJ; de Jong S; Kruyt FA
Drug Resist Updat; 2010; 13(1-2):2-15. PubMed ID: 20036602
[TBL] [Abstract][Full Text] [Related]
15. Targeting angiogenesis in head and neck cancer.
Seiwert TY; Cohen EE
Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
[TBL] [Abstract][Full Text] [Related]
16. The long road to colorectal cancer therapy: searching for the right signals.
Hollande F; Pannequin J; Joubert D
Drug Resist Updat; 2010; 13(1-2):44-56. PubMed ID: 20176501
[TBL] [Abstract][Full Text] [Related]
17. Endostatin: the logic of antiangiogenic therapy.
Abdollahi A; Hlatky L; Huber PE
Drug Resist Updat; 2005; 8(1-2):59-74. PubMed ID: 15939343
[TBL] [Abstract][Full Text] [Related]
18. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.
Wachsberger P; Burd R; Dicker AP
Clin Cancer Res; 2003 Jun; 9(6):1957-71. PubMed ID: 12796357
[TBL] [Abstract][Full Text] [Related]
19. [Dormant tumors and organs resistant to metastasis after gene transfer: dream and reality of anti-angiogenic gene therapy].
Li H; Dkhissi F; Grenet C; Soria C; Lu H
Therapie; 2001; 56(5):501-10. PubMed ID: 11806286
[TBL] [Abstract][Full Text] [Related]
20. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies.
Crawford Y; Ferrara N
Trends Pharmacol Sci; 2009 Dec; 30(12):624-30. PubMed ID: 19836845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
